RayKnowChina Research Map
Shortlist0

RecruitingNeuromyelitis optica spectrum disorderN/A

Registered title, quoted from ClinicalTrials.gov

Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. Led by Third Affiliated Hospital of Sun Yat-sen University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorThird Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06763848, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Women who are pregnant or breastfeeding.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06763848, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The inclusion criteria for the study are as follows:
  • clinical diagnosis of acute Neuromyelitis Optica Spectrum Disorders (NMOSD)
  • Age and Gender: Participants must be between 18 and 65 years old, inclusive, with no gender restrictions.
  • Serological Marker: Participants must test positive for AQP4-IgG using the cell-based assay (CBA) method.
  • Understanding and Consent: Participants or their legal representatives must be able to understand the study's purpose, demonstrate sufficient compliance with the study protocol, and sign the informed consent form.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Participants who cannot establish peripheral or central venous access, or have a history of allergic reactions to plasmapheresis.
  • Participants with contraindications to intravenous methylprednisolone treatment.
  • Participants who have used monoclonal antibodies in the last 6 months, or FcRn antagonists in the last 3 months.
  • Participants who must use ACE inhibitors (ACEI) within 1 week before the start of treatment or during the study, and cannot discontinue their use.
  • Severe Bleeding or Bleeding Disorders
  • Severe Heart Failure
  • Severe Infections

Quoted from ClinicalTrials.gov, NCT06763848, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06763848, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06763848